Topics

vaccines

‘Spikeopathy’: COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA
"Coronavirus genetic vaccines" are dangerous gene therapies sold with lies
2.4 Nonclinical Overview AZD1222
2.5 Clinical Overview: AZD1222 Marketing Authorisation Application - Primary Analysis (Data Cut-off 07 December 2020)
30 Doctors/Experts from all over the world warn about COVID vaccine
5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received through 28-FEB-2021
A Case Report: Multifocal Necrotizing Encephalitis and Myocarditis after BNT162b2 mRNA Vaccination against COVID-19
A cautionary note: Toxicity of polyethylene glycol 200 injected intraperitoneally into mice
A Critical Analysis of All-Cause Deaths during COVID-19 Vaccination in an Italian Province
A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations
A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells
A Novel Practical Approach for Directly Assessing COVID-19 Vaccine Efficacy against Hospitalization
A Population-Based Analysis of the Risk of Glomerular Disease Relapse after COVID-19 Vaccination
A Potential Role of the Spike Protein in Neurodegenerative Diseases: A Narrative Review
A Report on the U.S. Vaccine Adverse Events Reporting System (VAERS) of the COVID-19 Messenger Ribonucleic Acid (mRNA) Biologicals
A review of neurological side effects of COVID-19 vaccination
A Systematic Review of Autopsy Findings in Deaths after COVID-19 Vaccination
A Systematic Review of COVID-19 Vaccine-Induced Takotsubo Cardiomyopathy: A 2023 Update
Abnormal Clots and All-Cause Mortality During the Pandemic Experiment: Five Doses of COVID-19 Vaccine Are Evidently Lethal to Nearly All Medicare Participants
Abstract 10712: Mrna COVID Vaccines Dramatically Increase Endothelial Inflammatory Markers and ACS Risk as Measured by the PULS Cardiac Test: a Warning
Abstract 10712: Observational Findings of PULS Cardiac Test Findings for Inflammatory Markers in Patients Receiving mRNA Vaccines
Acute extensive pulmonary embolism after mRNA SARS-CoV-2 immunization
Acute Vertigo After COVID-19 Vaccination: Case Series and Literature Review
Acute-onset chronic inflammatory demyelinating polyneuropathy following AstraZeneca COVID-19 vaccine: a case report
Adverse events following COVID‐19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia
Adverse events of special interest following the use of BNT162b2 in adolescents: a population-based retrospective cohort study
Advisory Committee on Vaccines (Australia) - Meeting 22 - Minutes on Item 2.1 - BNT162b2 [mRNA] COVID-19 vaccine
Affidavit of LTC. Theresa Long M.D. in Support of a Motion for a Preliminary Injunction Order
Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines
Age-associated SARS-CoV-2 breakthrough infection and changes in immune response in a mouse model
All Deaths Reported to VAERS by Year
Alternate mechanisms of mRNA vaccine toxicity: which one is the main culprit?
An Independent Analysis of the Manufacturing and Quality Issues of the BNT162b BioNTech/Pfizer Quasi-vaccine based on the European Medicines Agency’s Public Assessment Report (EPAR)
An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies
An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam
An outbreak caused by the SARS-CoV-2 Delta variant (B.1.617.2) in a secondary care hospital in Finland, May 2021
An Update on COVID-19 Vaccine Induced Thrombotic Thrombocytopenia Syndrome and Some Management Recommendations
Analysis of COVID-19 vaccine death reports from the Vaccine Adverse Events Reporting System (VAERS) Database Interim: Results and Analysis
Analysis of Neurological Adverse Events Reported in VigiBase From COVID-19 Vaccines
Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries
Anaphylaxis-Induced Acute Coronary Syndrome Following Covid-19 mRNA-LNP Vaccination: Mechanisms and Therapeutic Approaches
Anecdotals (documentary)
Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination
Anti-recoverin Antibody-Associated Post-acute COVID Vaccination Syndrome After BNT162b2 in HLA-B27-Positive Spondylarthritis: A Case Report
Anti-science case study: COVID-19 vaccines’ effectiveness and safety exaggerated
Antigenic minimalism of SARS-CoV-2 is linked to surges in COVID-19 community transmission and vaccine breakthrough infections
APPENDIX 2.2: Cumulative and Interval Summary Tabulation of Serious and Non-Serious Adverse Reactions from Post-Marketing Data Sources
Approval letter: Biologics License Application (BLA) Approval for BioNTech (Pfizer) Manufacturing GmbH
Assessment of Myocardial 18F-FDG Uptake at PET/CT in Asymptomatic SARS-CoV-2–vaccinated and Nonvaccinated Patients
Assessment report: COVID-19 Vaccine Moderna
1444